See the DrugPatentWatch profile for Onivyde
Onivyde's price varies depending on the formulation and the region. A 5-milligram (mg) per milliliter (mL) oral suspension of Onivyde costs approximately $2,052 for a 50 mL bottle [1]. Another formulation, 20 mg/mL, has a similar price point. Pricing for specific patient access programs or institutional agreements may differ [1].
How is Onivyde's price determined?
The price of Onivyde is influenced by several factors, including manufacturing costs, research and development expenses, clinical trial data, regulatory approvals, and market demand [1]. The complexity of its liposomal formulation also contributes to the production cost.
When does Onivyde's patent expire?
The patent protection for Onivyde is an important factor influencing its long-term pricing and market availability. For detailed information on Onivyde's patent status and anticipated expiry dates, DrugPatentWatch.com is a valuable resource [2]. These patents generally grant market exclusivity for a specific period.
Are there any alternatives to Onivyde?
Onivyde is used for the treatment of pancreatic cancer. Other treatment options for pancreatic cancer exist, and the choice of therapy depends on various factors, including the stage of the disease, the patient's overall health, and previous treatments. These alternatives may include other chemotherapy regimens, targeted therapies, immunotherapy, or surgical interventions [1].
What is the dosage and administration of Onivyde?
Onivyde is administered orally. The recommended dosage and administration schedule are determined by a healthcare professional based on the patient's individual needs and medical condition. It is typically taken with food [1].
What clinical trials have been conducted for Onivyde?
Clinical trials are essential for establishing the safety and efficacy of drugs like Onivyde. Information on trials, including their design, patient populations, and reported outcomes, is often available through medical databases and the drug's manufacturer. These trials support regulatory approval and provide data on how the drug performs in real-world settings [1].
Who manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals [1].
What is the mechanism of action for Onivyde?
Onivyde is a liposomal formulation of irinotecan hydrochloride, a topoisomerase I inhibitor. It works by interfering with DNA replication in cancer cells, leading to their death [1]. The liposomal delivery system is designed to alter the pharmacokinetic profile of irinotecan, potentially improving its delivery to tumor sites and managing toxicity.
Are there patient assistance programs for Onivyde?
Pharmaceutical companies often offer patient assistance programs to help individuals afford their medications. Details about Onivyde's availability through such programs can typically be found on the manufacturer's website or by consulting a healthcare provider [1].
What is the treatment landscape for metastatic pancreatic cancer?
The treatment of metastatic pancreatic cancer is complex and continually evolving. Onivyde is one option within a broader therapeutic strategy that may include other chemotherapy agents, often used in combination. Research continues to explore new treatment modalities and combinations to improve outcomes for patients [1].
Sources:
1. https://www.drugpatentwatch.com/drugs/onivyde/
2. https://www.drugpatentwatch.com/